The Outcomes of Trabeculectomy following Anti-VEGF Treatments in Neovascular Glaucoma : A Systematic Review and Meta-Analysis Oral Presentation - Observational Study - General practitioner
Article Sidebar
-
Anti-VEGF, neovascular glaucoma, filtering surgery, trabeculectomy, IOP, BCVA, neovascularization
Abstract
Introduction
Neovascular glaucoma (NVG) is a secondary glaucoma that potentially causes blindness due to proliferation of fibrovascular tissue in the anterior chamber angle. Ischemia in retinal triggers a cascade of various angiogenic factors including vascular endothelial growth factor (VEGF) and interleukin-6 which lead to neovascularization. It was known that anti-VEGF inhibits the primary mediators of neovascularization and control intraocular pressure (IOP) in NVG.
Objective
To summarize outcome of anti-VEGF with trabeculectomy and applied in clinical practice.
Methods
PRISMA guideline was followed and analyzed the comparison with Revman (version 5.4). We used databases and professional websites published on eye conditions between 2013-2023 in English. All interventional and observational studies with 95% confidence interval (CI) were used. Risk of bias was measured using funnel plot. Outcomes measured were IOP, Best Corrected Visual Acquity (BCVA), neovascularization iris (NVI) recurrence before and after trabeculectomy.
Result
Six studies (199 eyes) showed a significant difference in IOP (MD=25.84, 95%CI 24.08-27.60, p< 0.00001) and NVI recurrence (RD=0.94, 95%CI 0.86-1.01, p<0.00001). While four studies (143 eyes) found there was a significant difference in BCVA (MD=0.21, 95%CI 0.06-0.37, p=0.008). The result of NVI should be interpreted with caution and not considered as definitive statement since the data was moderately heterogenic (I2=68% p=0.009).
Conclusion
It could be concluded there was a significant difference in IOP, BCVA, and NVI recurrence after given anti-VEGF with trabeculectomy. We could not conclude which anti-VEGF gave better result since there were lack of studies, low of studies quality, and heterogen data for NVI recurrence.
Full text article
References
C?lug?ru D, C?lug?ru M. Etiology, pathogenesis, and diagnosis of neovascular glaucoma. Int J Ophthalmol. 2022 Jun 18;15(6):1005-1010. doi: 10.18240/ijo.2022.06.20. PMID: 35814894; PMCID: PMC9203485.
Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2020 Feb 6;2(2):CD007920. doi: 10.1002/14651858.CD007920.pub3. Update in: Cochrane Database Syst Rev. 2023 Apr 3;4:CD007920. PMID: 32027392; PMCID: PMC7003996.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLOS Medicine [Internet]. 2021 [cited 2022 Feb 22];18(3):e1003583 [15p.]. Available from: https://doi.org/10.1371/journal.pmed.1003583
Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration. 2020.
Higashide, Tomomi et al. “Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma.” PloS one vol. 10,8 e0135766. 14 Aug. 2015, doi:10.1371/journal.pone.0135766
Sun, Y., Liang, Y., Zhou, P. et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol 16, 150 (2016). https://doi.org/10.1186/s12886-016-0327-9
Shi, L., Yang, J. & Lin, J. What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study. BMC Ophthalmol 19, 128 (2019). https://doi.org/10.1186/s12886-019-1138-6
Kobayashi, Satoshi et al. “Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma.” Journal of glaucoma vol. 25,3 (2016): 281-4. doi:10.1097/IJG.0000000000000211
Kitnarong N, Sriyakul C, Chinwattanakul S. A Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma. Ophthalmol Ther. 2015 Jun;4(1):33-41. doi: 10.1007/s40123-015-0033-3. Epub 2015 Mar 27. PMID: 25812531; PMCID: PMC4470984.
Elmekawey, Hany, and Amr Khafagy. “Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma.” Journal of glaucoma vol. 23,7 (2014): 437-40. doi:10.1097/IJG.0b013e3182946398
Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, Rani PK, Rao H, Singla S, Vijaya L. Neovascular glaucoma - A review. Indian J Ophthalmol. 2021 Mar;69(3):525-534.
Olmos LC, Lee RK. Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin. 2011 Summer;51(3):27-36. doi: 10.1097/IIO.0b013e31821e5960. PMID: 21633236; PMCID: PMC3107497.
Bai, Ling et al. “The Optimization of an AntiVEGF Therapeutic Regimen for Neovascular Glaucoma.” Frontiers in medicine vol. 8 766032. 10 Jan. 2022, doi:10.3389/fmed.2021.766032
Luo J, Yan Z, Jia Y, Luo R. Clinical Analysis of 42 Cases of Ocular Ischemic Syndrome. J Ophthalmol. 2018;2018:2606147
Mocanu C, Bar?scu D, Marinescu F, L?cr??eanu M, Iliu?i F, Simionescu C. [Neovascular glaucoma--retrospective study]. Oftalmologia. 2005;49(4):58-65
Authors
Copyright (c) 2023 Ni Putu Ayu Pande Arista Dewi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
